Vancouver, British Columbia, Canada – March 13, 2018 - InMed Pharmaceuticals Inc. (“InMed” or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the appointment of Eric Hsu, Ph.D., as Vice President of Preclinical Research and Development. In this capacity, Dr. Hsu will assume primary responsibility for advancing the Company’s cannabinoid biosynthesis manufacturing process and preclinical research on new drug candidates, including INM-085 for glaucoma and INM-405 for pain.
Dr. Hsu joins InMed with over 18 years of scientific leadership experience in developing novel gene transfer technologies and validation of preclinical drug candidates. Prior to joining InMed, Dr. Hsu held various positions with enGene Inc., including VP of Research and VP of Scientific Affairs and Operations. During his tenure, his responsibilities covered a wide array of activities, from benchtop research, formulation development and manufacturing process development to patent prosecution, vendor contract negotiations and execution, and research partnerships. He has co-authored over 25 publications and abstracts and holds five patents. Dr. Hsu received his Ph.D. from the University of Toronto in Medical Biophysics.
Eric A. Adams, InMed’s President & CEO, commented, “Dr. Hsu brings a tremendous scope and depth of scientific leadership to our Company. He has extensive experience to face several specific challenges which we will encounter as we develop our technologies, including biosynthesis and new product candidates.”
“InMed’s impressive technologies and focused approach to drug discovery and development have resulted in an exciting pipeline of drug candidates across many disease areas”, stated Dr. Hsu. “I am very excited to join the InMed team and look forward to assisting the Company in accomplishing its scientific and technology development objectives."
InMed is a fully-integrated biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel delivery approaches. Along with building and validating its proprietary drug-disease targeting platform and biosynthesis technologies for broad commercial use, InMed is currently developing pre-clinical product candidates INM-750 for the treatment of epidermolysis bullosa, INM-085 for the treatment of glaucoma and INM-405 for the treatment of pain. For more information, visit www.inmedpharma.com.
Contact: InMed Pharmaceuticals Inc.
Investor Relations and Corporate Development
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: Dr. Hsu advancing the Company’s cannabinoid biosynthesis manufacturing process and preclinical research on new drug candidates, including INM-085 for glaucoma and INM-405 for pain; accomplishing the Company’s scientific and technology development objectives; and developing INM-750 for the treatment of epidermolysis bullosa.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Dr. Hsu’s continued availability; positive drug development results; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: Dr. Hsu may become unwilling or unable to act as Vice President of Preclinical Research and Development; InMed may not be able to find suitable partners; economic or market conditions may worsen; and InMed’s proprietary platform technology, product pipeline and drug development programs may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.